Evacetrapib impacts cholesterol but doesn't reduce cardiovascular events
Cleveland Clinic researchers studying evacetrapib have shown that despite reducing levels of low-density lipoprotein (LDL, or "bad" cholesterol) by 37 percent and raising levels of high-density lipoprotein (HDL, or "good" ...
Apr 3, 2016
0
74